RESUMEN
Transect surveys of hamlet communities (Hypoplectrus spp., Serranidae) covering 14 000 m2 across 16 reefs off La Parguera, Puerto Rico, are presented and compared with a previous survey conducted in the year 2000. The hamlet community has noticeably changed over 17 years, with a > 30% increase in relative abundance of the yellowtail hamlet Hypoplectrus chlorurus on the inner reefs at the expense of the other hamlet species. The data also suggest that the density of H. chlorurus has declined and that its distribution has shifted towards shallower depths. Considering that H. chlorurus has been previously identified as one of the few fish showing a positive association with seawater turbidity on the inner reefs of La Parguera and that sedimentation of terrestrial origin has increased over recent decades on these reefs, it is proposed that turbidity may constitute an important but so far overlooked ecological driver of hamlet communities.
Asunto(s)
Lubina/fisiología , Animales , Lubina/clasificación , Arrecifes de Coral , Ecología , Explotaciones Pesqueras , Densidad de Población , Dinámica Poblacional , Puerto Rico , Agua de MarRESUMEN
AIMS: To evaluate linear growth assessment and the effect of an intervention on measurement accuracy in primary care practices (PCP) within eight US geographical areas. METHODS: In this multicentre randomised controlled intervention study, paediatric endocrine nurses as site coordinators (SC) visited 55 randomly assigned PCP to evaluate growth assessment of staff performing linear measurements. SC observed 127 measurers assessing a total of 878 children: 307 (baseline), 282 (3 months), and 289 (6 months). Accuracy was determined by SC re-measuring each child with correct technique and equipment. State of the art equipment and a standardised growth training session were provided to the intervention group (IG) following the baseline visit. SC repeated data collection at all PCP at 3 and 6 months. RESULTS: There were no baseline differences between IG and CG equipment, technique, or accuracy; only 30% of measurements were accurate (< or =0.5 cm from SC). Post-intervention, significantly more IG measurements were accurate: IG = 55%, CG = 37% at 3 months; IG = 70%, CG = 34% at 6 months. Odds ratio of accuracy for IG versus CG was 2.1 at 3 months and 4.5 at 6 months. At 6 months, mean difference from the SC measurements was 0.5 cm in IG and 1.1 cm in CG. CONCLUSIONS: In PCP, children are measured inaccurately. Our intervention significantly improved measurement accuracy. Improved accuracy could yield more rapid detection and diagnosis of paediatric growth disorders.
Asunto(s)
Estatura , Competencia Clínica/normas , Crecimiento , Adolescente , Niño , Preescolar , Educación en Enfermería , Humanos , Lactante , Recién Nacido , Enfermeras Practicantes/normas , Atención Primaria de Salud/normas , Sensibilidad y EspecificidadRESUMEN
INTRODUCTION: Precise measurements of children are critical for accurate growth assessment. Many children are referred to endocrine practices in error because heights are obtained but plotted on length growth charts, giving the appearance that growth has decelerated. METHOD: In an attempt to evaluate growth assessment in primary care practices (PCPs), we instituted a telephone survey to gather the following data: (a) how often children are measured, (b) the criteria for whether children are measured standing or lying, (c) the methods for measuring children, and (d) whether measurements are plotted on growth charts and by whom. RESULTS: In PCPs, children were reported to be measured at every visit or only at well child visits. The criteria most frequently used to determine when children should be measured standing was "if they can stand, they are measured standing." Significantly more pediatric practices than family practices measured children standing at the correct age. Heights were most often obtained on a scale with a floppy arm. All but 4 practices reported that measurements on growth charts were plotted by the nurse or physician. DISCUSSION: Many practices had an incorrect policy related to obtaining measurements of length versus height. Children are measured with the correct equipment in only 22% of PCPs for height and 12% of PCPs for length. Most PCPs are diligent about plotting growth data. Clearly, education of personnel in PCPs is crucial so that accurate growth measurements can be obtained, necessary referrals can be made, and unnecessary referrals can be avoided.
Asunto(s)
Estatura , Desarrollo Infantil , Enfermería Pediátrica/métodos , Atención Primaria de Salud/métodos , Recolección de Datos , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Evaluación en Enfermería/métodos , Valores de ReferenciaRESUMEN
Because of improved life expectancy for people with HIV infection, today's clinician needs to understand and manage chronic symptoms that limit function and quality of life. The authors describe two collaborative HIV symptom-management studies conducted by the Division of Intramural Research of the National Institute of Nursing Research. Studies such as these are necessary to provide nurses and other healthcare personnel with the knowledge essential for appropriate, comprehensive, and quality patient care.
Asunto(s)
Investigación en Enfermería Clínica , Infecciones por VIH/complicaciones , Grupo de Atención al Paciente , Enfermedad Crónica , Infecciones por VIH/enfermería , Humanos , Esperanza de Vida , National Institutes of Health (U.S.) , Proyectos de Investigación , Estados UnidosRESUMEN
Zidovudine-induced myopathy is characterized by reversible muscle weakness, wasting, myalgia, fatigue, and elevated creatine kinase (CK). Some zidovudine-treated patients with normal muscle strength experience excessive fatigue, myalgia, or transient mild CK elevations that improve when zidovudine is stopped. To determine the cause of these symptoms, we studied 13 physically fit, HIV-infected men who developed fatigue, myalgia, and reduced endurance, while taking zidovudine for a mean period of 20 months (2-39 months), with neurological evaluation and muscle biopsy processed for enzyme histochemistry and electron microscopy (EM). All subjects had normal muscle strength. In 6 of the 13 patients, muscle biopsies were normal by enzyme histochemistry. EM, however, demonstrated proliferation of normal or abnormal mitochondria, and increased amounts of lipid, glycogen, and lipofuscin. Electromyographic (EMG) studies (5/5) and serum CK (6/6) were normal. The other 7 individuals had signs of moderate to severe mitochondrial abnormalities shown by both light microscopy and EM, characterized by severe destruction, vacuolization, and rare paracrystalline inclusions. Most had elevated CK (4 out of 7) and normal EMG (5 out of 7). The severity of morphological abnormalities did not correlate with duration of HIV infection, zidovudine therapy, or zidovudine dosage. We conclude that in zidovudine-treated patients, symptoms of fatigue, myalgia, reduced endurance, and exercise intolerance represent early signs of zidovudine-induced mitochondriotoxicity, which causes an energy shortage within the muscle fibers even when muscle strength is still normal. Zidovudine, a DNA chain terminator, results in overt myopathy when a critical threshold of molecular, histological, and biochemical dysfunction of mitochondria is crossed, which seems to vary between individuals.
Asunto(s)
Enfermedades Musculares/patología , Zidovudina/efectos adversos , Adulto , Biopsia , Electromiografía , Electrofisiología , VIH , Humanos , Persona de Mediana Edad , Fatiga MuscularAsunto(s)
Hormona Liberadora de Gonadotropina/análogos & derivados , Pubertad Precoz/tratamiento farmacológico , Pamoato de Triptorelina/análogos & derivados , Estatura/efectos de los fármacos , Niño , Preparaciones de Acción Retardada , Femenino , Estudios de Seguimiento , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Masculino , Maduración Sexual/efectos de los fármacosRESUMEN
Because the pubertal growth spurt in boys appears to be mediated by both androgens and estrogens, we hypothesized that blockade of both androgen action and estrogen synthesis would normalize the growth of boys with familial male precocious puberty. To test this hypothesis, we studied nine boys (age range, 3.3 to 7.7 years) during treatment with an antiandrogen (spironolactone) or an inhibitor of androgen-to-estrogen conversion (testolactone), followed by treatment with both agents. After six months of observation without treatment, the first four boys received spironolactone for six months, followed by spironolactone and testolactone. The next five boys received testolactone for six months, followed by spironolactone and testolactone. Neither spironolactone nor testolactone, given alone, was satisfactory as a treatment for this condition. However, a combination of spironolactone and testolactone, given for at least six months, restored both the growth rate and the rate of bone maturation to normal prepubertal levels and controlled acne, spontaneous erections, and aggressive behavior. The combined therapy was associated with a significantly lower growth rate than testolactone alone (P less than 0.05) and a significantly lower rate of bone maturation than spironolactone alone (P less than 0.05). No important adverse effects were observed during combined treatment. Six of the nine boys continued to receive the combined therapy for an additional 12 months and maintained normal prepubertal rates of growth and bone maturation. The mean predicted height (+/- SEM) increased progressively during the combined treatment although the difference between the pretreatment and post-treatment predictions was not significant (169.5 +/- 2.8 at the end of treatment vs. 166.2 +/- 4.5 cm before treatment; P = 0.29). We conclude that blockade of both androgen action and estrogen synthesis with the combination of spironolactone and testolactone is an effective short-term treatment for familial male precocious puberty. Further study will be required, however, to assess the long-term outcome in boys who receive this treatment.
Asunto(s)
Pubertad Precoz/tratamiento farmacológico , Espironolactona/uso terapéutico , Testolactona/uso terapéutico , Agresión/efectos de los fármacos , Estatura , Niño , Preescolar , Depresión Química , Esquema de Medicación , Quimioterapia Combinada , Hormona Folículo Estimulante/sangre , Crecimiento/efectos de los fármacos , Humanos , Hormona Luteinizante/sangre , Masculino , Osteogénesis/efectos de los fármacos , Erección Peniana/efectos de los fármacos , Pubertad Precoz/genética , Espironolactona/administración & dosificación , Testolactona/administración & dosificaciónRESUMEN
Premature thelarche is a benign condition that affects young girls. In contrast, central precocious puberty is considered a more serious disorder that causes progressive secondary sexual development, accelerated growth and skeletal maturation, early epiphyseal fusion, and short adult stature. Differentiation between these 2 conditions is important, but may be difficult on clinical grounds, since patients with both disorders may present initially as isolated breast development. To examine the potential usefulness of gonadotropin measurements in distinguishing early central precocious puberty from premature thelarche, we measured basal and LHRH-stimulated plasma gonadotropin levels in 58 girls with idiopathic premature breast development. The girls were divided into six clinically distinct groups, based on the severity of clinical presentation, ranging from isolated breast development (group A) to complete secondary sexual development and accelerated growth and skeletal maturation (group F). The mean basal plasma LH levels and the peak LH response to LHRH stimulation were significantly less in girls with isolated thelarche (group A) than in girls with complete sexual development (group F). The mean basal plasma FSH levels did not differ between these groups, but the peak FSH response to LHRH was greater in girls with isolated thelarche than in girls with complete sexual development. Thus, girls with isolated premature thelarche had a FSH-predominant response to LHRH [mean ratio of peak LH to peak FSH, 0.29 +/- 0.10 (+/- SD)], while girls with complete sexual development had a LH-predominant response (peak LH/FSH, 4.16 +/- 1.80). All girls with isolated thelarche had peak LH/FSH ratios less than 1, and all girls with complete sexual development had a ratio greater than 1. Girls with early or intermediate manifestations of central precocious puberty, who had features of puberty in addition to breast development but lacked all of the features of group F, comprised groups B-E. These girls also had intermediate peak LH/FSH ratios, ranging from 0.29 +/- 0.10 (group B) to 3.35 +/- 2.66 (group E). We conclude that girls with early central precocious puberty frequently have LH and FSH responses to LHRH that are indistinguishable from the FSH-predominant responses of girls with isolated thelarche. These data are consistent with the hypothesis that premature thelarche and central precocious puberty may represent different positions along a continuum of hypothalamic LHRH neuron activation.
Asunto(s)
Mama/crecimiento & desarrollo , Hormona Liberadora de Gonadotropina , Gonadotropinas/sangre , Pubertad Precoz/diagnóstico , Niño , Preescolar , Ritmo Circadiano , Diagnóstico Diferencial , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Hormona Luteinizante/sangre , Pubertad Precoz/sangreRESUMEN
To determine whether puberty resumes normally after long term LHRH agonist (LHRHa) treatment, we studied 16 children with central precocious puberty treated with LHRHa (D-Trp6,Pro9,NEt-LHRH) for 1-4 yr (mean, 3.3 yr). Treatment was discontinued at a mean age of 11.6 +/- 1.3 (+/- SD) yr. Plasma hormone levels, growth velocity, rate of bone maturation, and pubertal stage were assessed at the end of treatment and 3 and 12 months later. Basal plasma sex steroid and basal and LHRH-stimulated gonadotropin levels returned to near-pretreatment levels 3 months after discontinuation of therapy and were fully restored to pretreatment levels at 12 months. Growth velocity, which had been 7.8 cm/yr before treatment, was stable after discontinuation of treatment at approximately 2.6 cm/yr. The predicted height, which had increased during treatment (P less than 0.01), remained stable at approximately 5 cm above the pretreatment predicted height. The rate of bone age advancement (delta bone age/delta chronological age) increased gradually from 0.4 at the end of treatment to the normal value of 0.9 12 months posttreatment. Breast and pubic hair pubertal stages, which were stable throughout treatment and were 4.0 +/- 0.8 (+/- SD) and 3.6 +/- 1.0 at the end of treatment, increased to 4.9 +/- 0.2 and 4.5 +/- 1.0. This approximated the normal rate of 1 stage/yr. Menses occurred in 8 of 12 girls within 1 yr after treatment and in an additional 3 by 20 months after treatment. Six of the girls had menstruated before treatment, and all of these menstruated within 14 months after discontinuing therapy. We conclude that gonadotropin and sex steroid secretion and the clinical progression through puberty appear to resume normally after discontinuation of long term LHRHa treatment of central precocious puberty. Long term follow-up will be required, however, to determine whether the improvement in predicted height of these patients will be achieved, and whether adult reproductive function will be normal.
Asunto(s)
Hormona Liberadora de Gonadotropina/análogos & derivados , Pubertad Precoz/tratamiento farmacológico , Pubertad , Pamoato de Triptorelina/análogos & derivados , Estatura , Desarrollo Óseo , Niño , Femenino , Estudios de Seguimiento , Hormonas Esteroides Gonadales/sangre , Hormona Liberadora de Gonadotropina/uso terapéutico , Gonadotropinas/sangre , Humanos , MasculinoRESUMEN
Blood pressure increases with age in normal children. This increase appears to be related to body size. To assess the role of body size as a determinant of blood pressure in precocious puberty, we compared the blood pressure of 81 children with precocious puberty with the blood pressure standards for normal children from the NHLBI Task Force on Blood Pressure Control in Children. Children with precocious puberty had significantly increased blood pressure for chronologic age (p less than 0.05) but generally appropriate blood pressure for height age or weight age. These data are consistent with the hypothesis that increased body size causes the increased blood pressure for chronologic age in children with precocious puberty. Physicians who evaluate such children should assess whether blood pressure is appropriate for height age rather than chronologic age.
Asunto(s)
Presión Sanguínea , Estatura , Peso Corporal , Pubertad Precoz/fisiopatología , Determinación de la Edad por el Esqueleto , Niño , Preescolar , Femenino , Humanos , Masculino , Factores SexualesRESUMEN
Adrenarche is a developmental change of the adrenal gland that results in increased secretion of adrenal androgens. This maturational process generally begins several years before activation of the hypothalamic-pituitary-gonadal axis (gonadarche). To study further the relationship between adrenarche and gonadarche, we examined adrenarche in patients with precocious puberty and in patients with isolated hypogonadotropic hypogonadism. Plasma dehydroepiandrosterone, dehydroepiandrosterone sulfate, androstenedione, and cortisol were measured basally and during an infusion of ACTH in 50 children with precocious puberty, 5 patients with isolated hypogonadotropic hypogonadism, 7 preadrenarchal children with constitutional short stature, 44 normal pubertal children, and 40 normal adults. Children with precocious puberty did not have a corresponding advance in the timing of adrenarche. Their basal and ACTH-stimulated adrenal androgen levels were markedly lower than those of normal children matched for pubertal stage (P less than 0.05) and were only slightly greater than those reported for normal children of the same age. Similarly, patients with isolated hypogonadotropic hypogonadism and delayed puberty had no corresponding delay of adrenarche. Their adrenal androgen levels were appropriate for chronological age. Thus, these data provide further support for the hypothesis that adrenarche and gonadarche are independent maturational events controlled by separate mechanisms.
Asunto(s)
Glándulas Suprarrenales/metabolismo , Andrógenos/metabolismo , Gónadas/fisiopatología , Hipogonadismo/fisiopatología , Sistema Hipotálamo-Hipofisario/fisiopatología , Pubertad Precoz/fisiopatología , Adolescente , Adulto , Andrógenos/sangre , Niño , Preescolar , Femenino , Humanos , Hidrocortisona/sangre , Hipogonadismo/sangre , Hipogonadismo/metabolismo , Lactante , Masculino , Pubertad Precoz/sangre , Pubertad Precoz/metabolismoAsunto(s)
Enfermedades del Sistema Nervioso Central/complicaciones , Odontogénesis , Pubertad Precoz/fisiopatología , Caracteres Sexuales , Determinación de la Edad por el Esqueleto , Determinación de la Edad por los Dientes , Niño , Preescolar , Estradiol/sangre , Femenino , Humanos , Masculino , Pubertad Precoz/sangre , Pubertad Precoz/etiologíaRESUMEN
The McCune-Albright syndrome is characterized by café au lait spots, fibrous dysplasia of bones, and sexual precocity. Girls with precocious puberty due to this syndrome have episodic increases in serum estrogen levels together with the formation of large ovarian cysts. The serum gonadotropin levels are typically suppressed, and the precocious puberty has not responded to treatment with long-acting analogues of luteinizing hormone-releasing hormone (LHRH). Encouraged by our initial success in a pilot study of one patient, we have now treated five girls with the McCune-Albright syndrome with the aromatase inhibitor testolactone, which blocks the synthesis of estrogens. Testolactone decreased the levels of circulating estradiol (P less than 0.05) and the ovarian volume (P less than 0.05), and there was a return to pretreatment levels after testolactone was stopped. During treatment, the peak responses of luteinizing hormone and follicle-stimulating hormone to stimulation by LHRH rose above suppressed pretreatment levels--significantly above pretreatment levels for follicle-stimulating hormone (P less than 0.02)--and then returned to pretreatment levels after testolactone was discontinued. Growth rates fell in three patients during treatment but could not be assessed in the other two because of bone deformities. The mean rate of bone maturation decreased and menses stopped in three of the four girls who were menstruating regularly. We conclude that testolactone is an effective treatment of precocious puberty in the McCune-Albright syndrome.
Asunto(s)
Inhibidores de la Aromatasa , Displasia Fibrosa Ósea/complicaciones , Displasia Fibrosa Poliostótica/complicaciones , Pubertad Precoz/tratamiento farmacológico , Testolactona/uso terapéutico , Desarrollo Óseo , Preescolar , Estradiol/sangre , Estrona/sangre , Femenino , Hormona Folículo Estimulante/sangre , Crecimiento , Humanos , Lactante , Hormona Luteinizante/sangre , Menstruación , Ovario/fisiopatología , Pubertad Precoz/complicaciones , Pubertad Precoz/fisiopatología , Maduración Sexual , Testolactona/administración & dosificaciónRESUMEN
The long-acting analogue of luteinizing hormone releasing hormone, D-Trp6-Pro9-NEt-LHRH (LHRHa), is effective in the short-term treatment of central precocious puberty. We report the results of two to four years of LHRHa therapy in 27 children with this disorder. Secondary sex characteristics regressed in most patients. Sex steroid levels and basal and LHRH-stimulated gonadotropin levels remained suppressed compared with pretreatment values. Linear growth rates decreased from 11.0 +/- 0.8 (SEM) cm/yr before treatment to 5.7 +/- 0.4 cm/yr at two years of treatment and 3.7 +/- 0.7 cm/yr at four years of treatment. Predicted heights by the Bayley-Pinneau method increased from 156.4 +/- 2.0 cm before treatment to 162.3 +/- 2.3 cm at two years and 163.4 +/- 2.4 cm at three years. Five patients treated for four years had a mean increase in predicted height of 5.5 cm. To date no adverse effects have been observed. However, the ultimate safety of this analogue is not known. We conclude that LHRHa appears to be an effective long-term therapy for central precocious puberty.
Asunto(s)
Desarrollo Óseo/efectos de los fármacos , Hormona Liberadora de Gonadotropina/análogos & derivados , Crecimiento/efectos de los fármacos , Pubertad Precoz/tratamiento farmacológico , Pamoato de Triptorelina/análogos & derivados , Estatura , Niño , Preescolar , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina/uso terapéutico , Humanos , Hormona Luteinizante/sangre , Masculino , Pubertad Precoz/sangre , Pubertad Precoz/fisiopatología , Maduración Sexual/efectos de los fármacos , Testosterona/sangreRESUMEN
Between 1979 and 1983, 129 children (95 girls) with precocious puberty were referred to the National Institutes of Health and received treatment for at least 6 months with the long-acting LHRH analogue D-Trp6-Pro9-NEt-LHRH. The majority (107 of 129) of the children had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis in association with hypothalamic hamartomas (24 of 107) or other central nervous system lesions (21 of 107), or idiopathic precocious puberty (62 of 107). Hypothalamic hamartomas or other central nervous system lesions were a frequent cause of central precocious puberty in girls (27 of 87), but idiopathic precocious puberty was still the most frequent diagnosis (63%). Idiopathic precocious puberty was uncommon in boys (6%). The patients with peripheral precocious puberty included six girls with McCune-Albright syndrome and six boys with familial male precocious puberty. These children had peripheral sex steroid secretion in the absence of hypothalamic-pituitary-gonadal axis maturation. The children with combined peripheral and central precocious puberty included nine children with congenital adrenal hyperplasia and one girl with a virilizing adrenal tumor. In the patients with central precocious puberty or combined peripheral and central precocious puberty, LHRHa therapy caused suppression of gonadotropin and sex steroid levels (P less than 0.001), stabilization or regression of secondary sexual characteristics, and decreases in growth rate and in the rate of bone age maturation (P less than 0.005). Patients with peripheral precocious puberty, however, had no significant change in gonadotropin or sex steroid levels, growth rate, or the rate of bone age maturation, and no improvement in secondary sexual characteristics. Thus, LHRHa is an effective treatment of central precocious puberty and combined peripheral and central precocious puberty, but is ineffective in the therapy of peripheral precocious puberty.
Asunto(s)
Hormona Liberadora de Gonadotropina/análogos & derivados , Pubertad Precoz/clasificación , Pubertad Precoz/tratamiento farmacológico , Pamoato de Triptorelina/análogos & derivados , Hiperplasia Suprarrenal Congénita/complicaciones , Niño , Preescolar , Preparaciones de Acción Retardada , Estradiol/sangre , Femenino , Displasia Fibrosa Poliostótica/complicaciones , Hormona Folículo Estimulante/sangre , Hormona Liberadora de Gonadotropina/administración & dosificación , Hormona Liberadora de Gonadotropina/uso terapéutico , Crecimiento , Hamartoma/complicaciones , Humanos , Neoplasias Hipotalámicas/complicaciones , Hormona Luteinizante/sangre , Masculino , National Institutes of Health (U.S.) , Pubertad Precoz/etiología , Caracteres Sexuales , Factores Sexuales , Testosterona/sangre , Estados UnidosRESUMEN
Seven children with central precocious puberty and either neurofibromatosis and/or optic gliomas were referred to the National Institutes of Health, Bethesda, Md, for evaluation and treatment with the long-acting luteinizing hormone releasing hormone analogue (LHRHa) D-Trp6-Pro9-NEt-LHRH. Only six of the seven children chose to receive treatment. Four children presented with neurofibromatosis, three of whom also had optic gliomas; the remaining three children had isolated optic gliomas, without other neurocutaneous stigmas. All had central precocious puberty mediated by activation of the hypothalamic-pituitary-gonadal axis. Six months of LHRHa therapy caused suppression of gonadotropin and sex steroid levels, stabilization or regression of secondary sexual characteristics, and decreases in growth velocity and the rate of bone age maturation. We conclude that LHRHa therapy is effective in the treatment of central precocious puberty secondary to neurofibromatosis and/or optic gliomas.
Asunto(s)
Neoplasias de los Nervios Craneales/complicaciones , Glioma/complicaciones , Hormona Liberadora de Gonadotropina/análogos & derivados , Neurofibromatosis 1/complicaciones , Enfermedades del Nervio Óptico/complicaciones , Pubertad Precoz/complicaciones , Neoplasias Cutáneas/complicaciones , Pamoato de Triptorelina/análogos & derivados , 17-alfa-Hidroxiprogesterona , Niño , Preescolar , Gonadotropina Coriónica/sangre , Cortodoxona/sangre , Neoplasias de los Nervios Craneales/fisiopatología , Estradiol/sangre , Femenino , Hormona Folículo Estimulante/sangre , Glioma/fisiopatología , Hormona Liberadora de Gonadotropina/uso terapéutico , Crecimiento/efectos de los fármacos , Humanos , Hidroxiprogesteronas/sangre , Hormona Luteinizante/sangre , Masculino , Neurofibromatosis 1/fisiopatología , Enfermedades del Nervio Óptico/fisiopatología , Pubertad Precoz/tratamiento farmacológico , Pubertad Precoz/fisiopatología , Neoplasias Cutáneas/fisiopatología , Testosterona/sangreRESUMEN
One hundred and one children with precocious puberty were given an oral examination. Dental root development was assessed using panoramic radiographs. All mandibular canines, pre-molars, and molars which could be visualized without apparent distortion were included. The patients were grouped for analysis according to the etiology of their precocity, e.g., McCune-Albright syndrome, familial male, congenital adrenal hyperplasia, central nervous system lesions, and idiopathic precocious puberty. Dental development was significantly retarded relative to their chronological age in patients with idiopathic precocious puberty. However, no significant abnormal dental development was detected in any of the other groups. Individual oral-facial growth and development remain the primary considerations for timing orthodontic treatment.
Asunto(s)
Odontogénesis , Pubertad Precoz/fisiopatología , Determinación de la Edad por el Esqueleto , Determinación de la Edad por los Dientes , Niño , Preescolar , Femenino , Humanos , Masculino , Pubertad Precoz/diagnóstico , Radiografía Panorámica , Diente/diagnóstico por imagenRESUMEN
To assess the role of somatomedin-C as a possible mediator of the growth spurt in children with central precocious puberty, we compared Sm-C levels in 40 children with central precocious puberty, 87 age-matched normal children, and 110 normal pubertal controls. Somatomedin C levels were significantly elevated for age in the children with precocious puberty (P less than 0.01), and were similar to the levels observed during normal puberty. The patients with precocious puberty were given the luteinizing hormone releasing hormone analogue D-Trp6-Pro9-NEt-LHRH (LHRHa) for 6 months. Treatment caused a significant decrease in secondary sexual characteristics, growth rate, plasma gonadotropins, sex steroids (estradiol in the girls and testosterone in the boys), and Sm-C levels. Growth during LHRHa treatment returned to the age-appropriate rate, whereas plasma Sm-C levels, although lower than pretreatment levels, remained significantly elevated for age (P less than 0.002). In addition, growth rates before and during treatment did not correlate with the plasma somatomedin C levels, nor did the decreases in growth rate during LHRHa therapy correlate with the decreases in somatomedin C levels. Growth rates did correlate significantly, however, with plasma estradiol levels in the girls (P less than 0.0005) and with plasma testosterone levels in the boys (P less than 0.025). We conclude that the growth spurt in children with precocious puberty cannot be explained by the plasma level of somatomedin C.